Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
51% Control Rate Achieved In Phase II Trial of Elderly Patients
Study: Partial Kidney Removal Leads to Greater Survival
Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
Two Children Achieve Remission With CD19 Immunotherapy
Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
Study: Oncotype DX Score Can Predict Local Recurrence
BRAF Mutation Testing Classifies Indeterminate FNA Samples
NCI CTEP Approved Trials For the Month of March
FDA Approves Lymphoseek For Imaging Lymph Nodes
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
